The Society for Immunotherapy of Cancer (SITC) is thrilled to announce its 2022 Annual Awards recipients, recognizing individuals who have notably contributed to the cancer immunotherapy field. SITC will honor the recipients at its 37th Annual Meeting & Pre-Conference Programs, taking place November 8–12, 2022, in Boston, MA and virtually.
MILWAUKEE, Aug. 30, 2022 /PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC) is thrilled to announce its 2022 Annual Awards recipients, recognizing individuals who have notably contributed to the cancer immunotherapy field. SITC will honor the recipients at its 37th Annual Meeting & Pre-Conference Programs, taking place November 8–12, 2022, in Boston, MA and virtually.
"The Annual Awards shine a spotlight on individuals and their important work, which directly impacts patients and enhances the immuno-oncology field," said SITC President Patrick Hwu, MD. "SITC is pleased to showcase the 2022 recipients, and we look forward to celebrating them at SITC 2022 this fall."
The 2022 recipients are:
2022 SITC Lifetime Achievement Award
Michael B. Atkins, MD – Georgetown Lombardi Comprehensive Cancer Center
2022 Pedro J. Romero Service to JITC Award
Cornelis J.M. Melief, MD, PhD – Leiden University Medical Center & ISA Pharmaceuticals
2022 Tara Withington Public Service Award
Bernard A. Fox, PhD – Earle A. Chiles Research Institute, Providence Cancer Institute
2023 Richard V. Smalley Memorial Award
Robert D. Schreiber, PhD – Washington University School of Medicine
To learn more about the Annual Awards and to view past recipients, visit SITC's website. SITC will announce a call for nominations for the 2023 Annual Awards in the spring.
About SITC
Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word "cure" a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on Twitter, LinkedIn, Facebook and YouTube.
Media Contact
Thomas Martin, Society for Immunotherapy of Cancer, 414-271-2456, [email protected]
SOURCE Society for Immunotherapy of Cancer
Share this article